Market capitalization | $21.34b |
Enterprise Value | $26.77b |
P/E (TTM) P/E ratio | 21.85 |
EV/FCF (TTM) EV/FCF | 27.37 |
EV/Sales (TTM) EV/Sales | 3.56 |
P/S ratio (TTM) P/S ratio | 2.84 |
P/B ratio (TTM) P/B ratio | 1.69 |
Dividend yield | 0.92% |
Last dividend (FY23) | $0.96 |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
30 Analysts have issued a Zimmer Biomet Holdings, Inc. forecast:
30 Analysts have issued a Zimmer Biomet Holdings, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 7,525 7,525 |
5%
5%
|
|
Gross Profit | 4,652 4,652 |
2%
2%
|
|
EBITDA | 2,319 2,319 |
5%
5%
|
EBIT (Operating Income) EBIT | 1,355 1,355 |
5%
5%
|
Net Profit | 997 997 |
97%
97%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Zimmer Biomet Holdings, Inc. provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Zimmer Biomet Holdings was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
Head office | United States |
CEO | Ivan Tornos |
Employees | 18,000 |
Founded | 1927 |
Website | www.zimmerbiomet.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.